Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

Featuring an interview with Dr L Elizabeth Budde, including the following topics:

Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study (17:30)Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and polatuzumab vedotin in the second-line setting (23:18)Case: A woman in her early 70s with R/R DLBCL receives glofitamab monotherapy in the third-line setting (32:52)Case: A man in his early 80s with R/R DLBCL experiences disease progression after lisocabtagene maraleucel therapy, which was bridged with epcoritamab and gemcitabine/oxaliplatin (37:35)

CME information and select publications